EZH2 is a well-known oncogene associated with a more aggressive form and poorer prognosis of many cancers, including melanoma, squamous cell carcinoma (SCC), and BCC, with demonstrated increased expression in SCC [compared to normal skin and SCC precursor actinic keratosis (AK)] (61) and aggressive BCC (62). This evidence concerns the gene EZH2 and skin basal cell carcinoma.